By Tomi Kilgore, MarketWatch
The number of deaths in the U.S. as a result of the coronavirus that causes COVID-19 surged past the 200,000 mark, while the global count climbed closer to 1 million, while Johnson & Johnson provided a dose with regards to its vaccine candidate.
The sobering climb in the nation’s death toll comes while President Donald Trump continues to tout his administration’s handling of the pandemic at a largely maskless campaign rally in Pennsylvania . He also mocked presidential candidate Joe Biden for wearing masks, even as his administration’s health experts urged all Americans to wear face coverings to guard against the spread of the deadly contagion.
The U.S. recorded at least 942 new coronavirus deaths on Tuesday, more than double the 428 deaths recorded the day before, even as the daily new case tally fell to 37,293 from 54,874. The new case tally was 10%, below the average of 41,490 cases a day over the past week, which was a 13% increase from the average two weeks earlier, New York Times data show .
In total, the U.S. case tally rose to 6,921,817 while the death toll climbed to 201,459, according to data aggregated by Johns Hopkins University , both by far the highest numbers in the world. Globally, cases grew to 31717,955 and deaths rose to 973,176.
In the U.S., 21 states are showing increases in new cases in the past week, according to JHU data . Among those states, those with the highest new daily counts are Texas at 6,885, Wisconsin at 1,672, Oklahoma at 1,164, New York at 754 and Colorado at 654.
There are 29 states in which at least 5% of COVID-19 tests are positive, led by Arkansas at 20.7%, South Dakota at 17.9%, Idaho at 17.5%, Wisconsin at 17.3% and Iowa at 15.8%. According to the World Health Organization, positivity rates should remain below 5%.
The New York Times
Concerns over the potential effects of a rise in cases and deaths, as the pandemic carries on until the fall and winter months, spilled over onto Wall Street, as the Dow Jones Industrial Average /zigman2/quotes/210598065/realtime DJIA +0.95% tumbled 496 points, or 1.8%, and the S&P 500 index /zigman2/quotes/210599714/realtime SPX +0.58% slid 2.1%. Boston Federal Reserve President Eric Rosengren said he was less optimistic about the economic outlook than his colleagues.
“I am concerned that a second wave of COVID-19 infections this fall and winter is likely, which could cause some states to impose new restrictions on mobility and face-to-face interactions,” Rosengren said, as MarketWatch’s Greg Robb reported.
On the bright side, J&J /zigman2/quotes/201724570/composite JNJ +0.46% said it launched a pivotal global Phase 3 trial of its COVID-19 vaccine candidate being developed by its Janssen Pharmaceutical subsidiary. The randomized, double-blind, placebo-controlled trial is studying the safety and efficacy of a single vaccine in up to 60,000 adults.
There are now four experimental coronavirus vaccine candidates in late-stage studies, including candidates developed by AstraZeneca PLC /zigman2/quotes/200304487/composite AZN +0.76% /zigman2/quotes/203048482/delayed UK:AZN +0.64% and the University of Oxford, BioNTech SE /zigman2/quotes/214419716/composite BNTX -0.75% and Pfizer Inc. /zigman2/quotes/202877789/composite PFE +0.36% , Moderna Inc. /zigman2/quotes/205619834/composite MRNA +3.82% and J&J. There are others in earlier-stage trials.
Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases, told Congress Wednesday that he expects to see data from the Phase 3 trials, indicating whether those vaccines are safe and effective, by “November or December” of this year.
Meanwhile, President Trump reportedly said at the Pennsylvania rally that a vaccine won’t only be developed, but distributed “ very very shortly .” He also said that his early and aggressive actions saved millions of lives.